Chang Fa Wang

6559282, May 6, 2003

Jan 25, 2001

09/770014

Chang Yi Wang - Cold Spring Harbor NY

United Biomedical, Inc. - Hauppauge NY

C07K 500

530324, 530350, 5303871, 5303881

The present invnetion is directed to novel peptide immunogens for eliciting antibodies to LHRH comprising artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity. The artificial Th epitopes are covalently linked to LHRH and optionally an immunostimulatory seqence.

6713301, Mar 30, 2004

Nov 29, 2000

09/701588

Chang Yi Wang - Cold Spring Harbor NY

United Biomedical, Inc. - Hauppauge NY

C12N 506

435328, 530350

The present invention is directed to novel artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity when used in peptide immunogens comprising B cell epitopes or peptide haptens, a target antigenic site of a target antigen for eliciting antibodies thereto. The artificial Th epitopes are covalently linked to the target antigenic site and and optionally an immunostimulatory sequence to provide effective and safe peptide immunogens.

6780969, Aug 24, 2004

Dec 22, 2000

09/747802

Chang Yi Wang - Cold Spring Harbor NY

United Biomedical, Inc. - Hauppauge NY

A61K 3800

530324, 4241981, 530313, 530326, 530350

The invention provides a peptide immunogen comprising a FAFSD target peptide or an anlogue thereof, covalently linked to a helper T cell epitope and optionally to an invasin immunostimulatory domain. The present invention also provides for the use of such peptide immunogens to elicit the production in mammals of high titer polyclonal antibodies, which are specific to the FAFSD target peptide. The peptide immunogens are expected to be useful in evoking antibodies that prevent the adherence of and other enterobacteria to the bladder mucosa for protection against urinary tract infection.

6811782, Nov 2, 2004

Dec 1, 2000

09/701623

Chang Yi Wang - Cold Spring Harbor NY
Alan M. Walfield - Huntington Station NY

United Biomedical, Inc. - Hauppauge NY

A61K 39385

4241851, 4241931, 530324

The invention provides peptides comprising a sequence homologous to a portion of the third constant domain of the epsilon heavy chain of IgE, covalently linked to either (1) a carrier protein, or (2) a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the production in mammals of high titer polyclonal antibodies, which are specific to a target effector site on the epsilon heavy chain of IgE. The peptides are expected to be useful in pharmaceutical compositions, to provide an immunotherapy for IgE-mediated allergic diseases.

6906169, Jun 14, 2005

May 25, 2001

09/865294

Chang Yi Wang - Cold Spring Harbor NY, US

United Biomedical, Inc. - Hauppauge NY

C07K007/00
C07K001/00
C07K014/00
C07K016/00
A61K038/00

530326, 530324, 530350, 530403, 530806, 530810

The present invention relates to a composition comprsing a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the Aβ peptide and generate antibodies, which are highly cross-reactive to the soluble Aβpeptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble Aβpeptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the “soluble Aβ-derived toxins”; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.

7501494, Mar 10, 2009

Jan 15, 2003

10/342959

Shugene Lynn - Taoyuan, TW
Chang Yi Wang - Cold Spring Harbor NY, US

United Biomedical, Inc. - Hauppauge NY

C07K 16/00
A61K 39/395

5303871, 4241301

This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgGantibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.

7648701, Jan 19, 2010

Nov 24, 2003

10/723207

Chang Yi Wang - Cold Spring Harbor NY, US
Alan M. Walfield - Huntington Station NY, US

United Biomedical, Inc. - Hauppauge NY

A61K 39/395
A61K 39/00
A01N 37/18
A61K 38/00
C07K 14/00
C07K 17/00
C12P 21/08

4241301, 4241331, 4241341, 4241921, 514 2, 530350, 5303871, 5303873

The invention provides peptides comprising a sequence homologous to a portion of the third constant domain of the epsilon heavy chain of IgE, covalently linked to either (1) a carrier protein, or (2) a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the production in mammals of high titer polyclonal antibodies, which are specific to a target effector site on the epsilon heavy chain of IgE. The peptides are expected to be useful in pharmaceutical compositions, to provide an immunotherapy for IgE-mediated allergic diseases.

7872110, Jan 18, 2011

Sep 9, 2008

12/207034

Shugene Lynn - Taoyuan, TW
Chang Yi Wang - Cold Spring Harbor NY, US

United Biomedical, Inc. - Hauppauge NY

C07H 23/00
A61K 39/395
C12N 15/09

536 231, 4241301, 435455

This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgGantibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.